Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study
- ŞİMŞEK, MELİH
- Gumus, Mahmut
- TÜRK, HACI MEHMET
- ŞEKER, Mesut
- Isikdogan, Abdurrahman
- Bilici, Ahmet
- Dane, Faysal
- Oven, Bala B.
- Turken, Orhan
- Kalkan, Ziya
- Tekin, Omer
- Firat, Sedat T.
- AKSOY, ASUDE
- Teker, Fatih
- Celik, Sinemis
- Ozcelik, Melike
- Coban, Ezgi
- Tanrikulu, Eda
- Cakir, Emre
- HACIBEKİROĞLU, İLHAN
- Erdemoglu, Engin
- Demirtas, Derya
- Perkin, Perihan
- Ozturk, Akin
- Geredeli, Caglayan
- KORAL, LOKMAN
- SÜMBÜL, BİLGE
- Aydin, Sabin Goktas
- YASİN, Ayşe İrem
DOIAbstract
Aim: To compare the seropositivity rate of cancer patients with non-cancer controls after inactive SARS-CoV-2 vaccination (CoronaVac) and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 non-cancer volunteers. An IgG level >= 50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccin...
%2C_National_Museum_of_Health_and_Medicine_(5243638771).jpg%3Fwidth%3D300&w=3840&q=75)
Add to ORKG